T1	intervention 12 23	anastrozole
T2	age 645 656	45-57 years
T3	eligibility 296 363	Patients with chemotherapy-induced ovarian function failure (CIOFF)
T4	eligibility 194 294	postmenopausal women with hormone receptor-positive early breast cancer after 2-3 years of tamoxifen
T5	total-participants 825 828	395
T6	total-participants 868 871	261
T8	outcome 1296 1312	experiencing OFR
T9	outcome 1351 1383	distant recurrence-free survival
T10	outcome 1448 1464	overall survival
T11	iv-bin-abs 1318 1320	39
T12	outcome 1545 1548	HRs
T13	outcome 1656 1704	5-year rate for distant recurrence-free survival
T14	outcome 1775 1798	5-year overall survival
T15	iv-bin-percent 1709 1714	76.9%
T16	cv-bin-percent 1738 1743	92.1%
T17	iv-bin-percent 1799 1804	80.8%
T18	cv-bin-percent 1809 1814	94.4%
